Invasive Pneumococcal Disease Study

Association Clinique Thérapeutique Infantile du val de Marne1,369 enrolled

Overview

After 7 then 13 valent pneumococcal conjugate vaccine implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.

Study Type

OBSERVATIONAL

Enrollment

1,369

Conditions

Pneumococcal Infections Pneumococcal Conjugate Vaccine Antibiotic Treatment Mortality

Interventions

observational studyOTHER

observational study

Eligibility

Sex: ALLMin age: 1 DayMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood PCR. Exclusion Criteria: * Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory

Locations (1)

ACTIV

Créteil, France

RECRUITING

Outcomes

Primary Outcomes

Severity of invasive pneumococcal disease

Number of severe cases according to age and pneumococcal serotypes distribution

Time frame: before hospital discharge

Secondary Outcomes

Impact of vaccines

Number of invasive pneumococcal disease according to vaccine serotypes

Time frame: before hospital discharge

Central Contacts

Levy Corinne

CONTACT

1 48 85 04 04 corinne.levy@activ-france.fr

Bechet Stephane

CONTACT

1 48 85 96 68 stephane.bechet@activ-france.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.